## TR-1: Standard form for notification of major holdings

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached <sup>ii</sup> :				Immupharma plc		
1b. Please indicate	if the issuer is a non-l	<b>JK issuer</b> (plea	ase mark	with an "X" if appropria	ate)	
Non-UK issuer						
2. Reason for the no	tification (please mark	the appropriate	box or l	boxes with an "X")		
An acquisition or dis	posal of voting rights					Х
An acquisition or dis	posal of financial inst	ruments				
An event changing t	he breakdown of votii	ng rights				
Other (please speci	fy) <sup>iii</sup> :					
3. Details of person	subject to the notifica	tion obligation	n <sup>iv</sup>			
Name	Name			Lanstead Capital Investors LP		
City and country of registered office (if applicable)						
4. Full name of shar	reholder(s) (if different f	rom 3.) <sup>v</sup>				
Name						
City and country of registered office (if applicable)						
5. Date on which the threshold was crossed or reached <sup>vi</sup> :			22/5/2025			
6. Date on which issuer notified (DD/MM/YYYY):			27/5/2025			
7. Total positions of	person(s) subject to the	he notification	obligat	ion		
	% of voting rights attached to shares (total of 8. A)	% of voting i through fina instrumer (total of 8.B 1 2)	ncial nts	Total of both in % (8.A + 8.B)	Total number of votir rights of issuer <sup>vii</sup>	ng
Resulting situation on the date on which threshold was crossed or reached	12.99%	0.00%		12.99%	499,723,932	
Position of previous notification (if applicable)	16.13%	0.00%		16.13%		

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached <sup>VIII</sup> A: Voting rights attached to shares				
Class/type of	Number of voting rig	ghts <sup>ix</sup>	% of voting rights	
<b>shares</b> ISIN code (if possible)	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Ordinary Shares ISIN: GB0033711010	64,932,129	0	12.99%	0.00%

SUBTOTAL 8. A

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))				
Type of financial instrument	Expiration date <sup>x</sup>	Exercise/ Conversion Period <sup>xi</sup>	Number of voting rights that may be acquired if the instrument is exercised/converted.	% of voting rights
N/A				
		SUBTOTAL 8. B 1		

B 2: Financial In (DTR5.3.1.1 (b))	struments with s	similar economic	effect according t	to Art. 13(1)(b) of Di	rective 2004/109/EC
Type of financial instrument	Expiration date <sup>x</sup>	Exercise/ Conversion Period <sup>xi</sup>	Physical or cash settlement <sup>xii</sup>	Number of voting rights	% of voting rights
N/A					
		·	SUBTOTAL 8.B.2		

<b>9. Information in relation</b> applicable box with an "X")	to the person subject to the	notification obligation (plea	se mark the		
Person subject to the notific	Person subject to the notification obligation is not controlled by any natural person or legal entity and does not				
control any other undertakin	ng(s) holding directly or indirect	ly an interest in the (underlyin	g) issuer <sup>xiii</sup>	Х	
Full chain of controlled unde	ertakings through which the voti	ng rights and/or the			
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity <sup>XiV</sup> (please add additional rows as necessary)					
Name <sup>xv</sup>	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equ is higher than the not threshold		
N/A					

10. In case of proxy voting, please identify:	
Name of the proxy holder	
The number and % of voting rights held	
The date until which the voting rights will be held	

11. Additional information <sup>xvi</sup>		

FIACE OF COMPLETION	
Date of completion	27/5/2025

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

HOLZDLFLEELFBBB